Selection of patients eligible for implantable cardioverter defibrillator: beyond left ventricular ejection fraction

Area of Science:

• Cardiology
• Genetics
• Medical Imaging

Background:

• Implantable cardioverter defibrillators (ICDs) are crucial for primary prevention in cardiomyopathies.
• Left ventricular ejection fraction (LVEF) alone is insufficient for optimal ICD candidate identification.
• Balancing arrhythmic risk, implantation risks, and device costs is essential.

Purpose of the Study:

• To evaluate the efficacy of genetic analysis and cardiac MRI in improving ICD selection for primary prevention.
• To identify better biomarkers for predicting sudden cardiac death risk in cardiomyopathy patients.

Main Methods:

• Review of current literature on ICD selection criteria.
• Analysis of studies incorporating genetic testing in cardiomyopathy patients.
• Assessment of cardiac magnetic resonance imaging (CMR) for myocardial fibrosis characterization.

Main Results:

• LVEF is a limited predictor of benefit from primary prevention ICDs.
• Genetic analysis can identify individuals at higher risk for ventricular arrhythmias.
• Cardiac MRI-detected myocardial fibrosis correlates with increased risk of sudden cardiac death.

Conclusions:

• Genetic analysis and CMR imaging significantly enhance the identification of patients who will benefit from primary prevention ICDs.
• Integrating these advanced techniques improves risk stratification beyond traditional LVEF measures.
• This approach optimizes resource allocation and patient outcomes in cardiomyopathy management.